Should I buy or sell Rain Oncology stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares. View RAIN analyst ratings or view top-rated stocks .

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.06.

What ETF holds Rain Oncology's stock?

Range Cancer Therapeutics ETF holds 100,278 shares of RAIN stock, representing 1.27% of its portfolio.

When did Rain Oncology IPO?

Rain Oncology (RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

NASDAQ:RAIN

Rain Oncology (RAIN) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free RAIN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.21
▼
$1.21
50-Day Range: $1.20
▼
$1.24
52-Week Range: $0.82
▼
$11.32

Volume: N/A
Average Volume: 550,818 shs
Market Capitalization: $44.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Rain Oncology alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Rain Oncology Stock (NASDAQ:RAIN)

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

RAIN Stock News Headlines

April 18, 2024 | omaha.com

Prince William returns to public duties for first time since Kate's cancer diagnosis

April 18, 2024 | mirror.co.uk

Where the original five Oasis members are now - heart attack, divorces and tonsil cancer

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 18, 2024 | msn.com

Prince William makes first public appearance since Kate’s cancer diagnosis

April 16, 2024 | uk.sports.yahoo.com

Rain washes away tonight’s Chicago White Sox game vs. the Kansas City Royals

April 14, 2024 | msn.com

Founder of 'The Cure Starts Now' takes message on cancer research to Washington

April 12, 2024 | msn.com

Deadly weather pummels much of Gulf Coast with tornadoes, torrential rain

April 12, 2024 | sports.yahoo.com

Rain forces postponement of Twins-Tigers game. They’ll play a doubleheader on Saturday

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 12, 2024 | msn.com

Columbus Weather: Rain sticks around Thursday; severe storms possible this afternoon

April 12, 2024 | msn.com

Heavy rain and gusty winds will make for a messy Friday in Maine

April 12, 2024 | msn.com

Gusty wind, occasional rain, thunder leads to a raw and unpleasant Saturday next

April 11, 2024 | msn.com

OJ Simpson dead of cancer at 76

April 11, 2024 | msn.com

O.J. Simpson dies at 76 after battle with cancer, family says

April 11, 2024 | msn.com

Weather Impact Day on Thursday due to heavy rain, storms

April 10, 2024 | msn.com

Green family cycling team beat rain, snow and hills to reach John O'Groats

April 10, 2024 | msn.com

Experimental treatment would help patients grow new livers

April 10, 2024 | msn.com

Weather Impact Day on Thursday due to heavy rain

April 9, 2024 | mirror.co.uk

Woman with mastectomy scars will be first to run London Marathon topless after cancer fight

April 9, 2024 | msn.com

Brave cancer survivors' 80-mile charity walk from Stoke-on-Trent to Wales

April 8, 2024 | msn.com

Rathdrum Cancer Support officially opens new facility

April 3, 2024 | msn.com

Nor'easter Will Bring Heavy Rain, Gusty Winds, Snow

April 2, 2024 | msn.com

Shannen Doherty has decided to 'downsize' as she lives with stage 4 cancer

April 2, 2024 | msn.com

Arizona congressman Raúl Grijalva says he has cancer, but plans to work while undergoing treatment

April 2, 2024 | chicago.suntimes.com

Ryne Sandberg, fighting prostate cancer, throws out first pitch at Cubs’ home opener

April 2, 2024 | msn.com

Lancaster County father and autism awareness advocate dies of brain cancer

April 2, 2024 | msn.com

Clouds and rain expected in Texas during the total solar eclipse

See More Headlines

Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:RAIN
CUSIP: N/A
CIK: 1724979
Web: www.rainthera.com
Phone: 510-953-5559
Fax: N/A
Employees: 63
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,720,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -82.96%
Return on Assets: -68.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.58
Quick Ratio: 5.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.11 per share
Price / Book: 0.39

Miscellaneous

Outstanding Shares: 36,380,000
Free Float: 30,047,000
Market Cap: $44.02 million
Optionable: Optionable
Beta: 0.27

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Avanish Vellanki M.B.A. (Age 49)
Co-Founder, CEO & Chairman
Comp: $959.75k
Dr. Robert C. Doebele M.D. (Age 53)
Ph.D., Co-Founder, Chairman of Scientific Advisory Board, President & CSO and Chief Medical Officer
Comp: $700.56k
Ms. Josephine Bruce (Age 45)
Principal Financial & Accounting officer
Ms. Theresa O'Connell M.S.
Director of Corporate Development & Operations
Mr. Erik Atkisson (Age 52)
General Counsel & Chief Compliance Officer
Ms. Charmi Turner
Vice President of People & Culture
Ms. Vijaya Tirunagaru Ph.D.
Senior VP & Head of Research
Dr. Nora Ku M.D.
MD & VP of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RAIN Stock Analysis - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings or view top-rated stocks.
How were Rain Oncology's earnings last quarter?: Rain Oncology Inc. (NASDAQ:RAIN) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.06.
What ETF holds Rain Oncology's stock?: Range Cancer Therapeutics ETF holds 100,278 shares of RAIN stock, representing 1.27% of its portfolio.
When did Rain Oncology IPO?: Rain Oncology (RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

This page (NASDAQ:RAIN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rain Oncology (RAIN) Stock Price, News & Analysis

About Rain Oncology Stock (NASDAQ:RAIN)

RAIN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RAIN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info